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ABSTRACT:
Beta-catenin is an essential cell adhesion and signaling protein, associated with
high prolactin levels in rat pituitary tumor cells. It has been shown that phosphorylation
affects the location and activity of β-catenin. Glycogen synthase kinase (GSK3-β) is a
serine-threonine kinase that phosphorylates β-catenin on N-terminal residues, targeting it
for proteasomal degradation. Studies have shown that C-terminal tyrosine
phosphorylation decreases the association of β-catenin with cadherin. In 235-1 rat
pituitary tumor cells, our lab has shown that the glucocorticoid analog dexamethasone
(Dex) decreases the half- life of β-catenin while increasing the activity of GSK3-β. The
current study was undertaken to examine whether active GSK3-β is necessary for the
regulation of β-catenin in Dex-treated cells. Duplicate cultures of 235-1 cells were
grown for four days in the presence of 100 nM Dex. To inhibit the activity of GSK3-β,
control and Dex-treated cells were treated with 20 mM LiCl, a known inhibitor of GSK3β activity. Cell lysates were collected and analyzed by Western blotting.
Phosphorylation-specific antibodies were used to detect levels of phosphorylated βcatenin (Ser 33/37/Thr 41) and (Ser 45/Thr41), active GSK3-β (Tyr 216) and inactive
GSK3-β (Ser 9). Additional experiments examined tyrosine phosphorylated β-catenin
through immunoprecipitation us ing a phosphotyrosine specific antibody, and by using a
LAR tyrosine phosphatase which removes phosphates from ß-catenin. Using λphosphatase, phosphates were removed nonspecifically from Ser, Thr, and Tyr residues
in β-catenin to evaluate total phospho rylation. After four days of treatment with Dex, βcatenin levels were reduced by approximately 50%. Levels of active GSK3-β (Tyr 216)
were increased in Dex-treated cells and levels of inhibited GSK3-ß (Ser 9) were
decreased in Dex-treated cells. This shows that Dex treatment alters activation of GSK3ß and likely functions in the regulation of β-catenin in 235-1 cells. Tyrosine C-terminal
phosphorylation of ß-catenin leads to a loss of cell- to-cell adhesion, which would lead to
morphological changes. Microscopic examination of Dex-treated cells showed the
presence of more rounded cells than control cells. Therefore, phosphorylation studies
were conducted to examine changes in tyrosine C-terminal phosphorylation. These
studies demonstrated no detectable alterations in tyrosine C-terminal phosphorylation;
however, the changes in cellular morphology suggest a loss of the cadherin-catenin
adhesion complex in Dex-treated cells. In Dex-treated cells λ-Phosphatase removed
phosphates in one major step. However, in control cells an additional step was needed to
remove phosphates from β-catenin, indicating that there is an alteration in phosphorylated
β-catenin in Dex-treated cells. Dex-treated cells showed an increase in the amount of
phosphorylated (Ser 45/Thr41 and Ser33/37/Thr41) ß-catenin. After a 24 hour treatment
with LiCl, there was a decrease in the amount of Ser33/37/Thr41 phosphorylated ßcatenin. Phosphorylation on Ser 45 was still present after treatment with LiCl indicating
that two separate kinases phosphorylate ß-catenin. Furthermore, ß-catenin levels were
restored, even though there was no apparent change in the level of active GSK3- β . These
data suggest that the presence of Dex caused an increase in the degradation rate of βcatenin by stimulating GSK3-β activity. Supported by NSF grant #IBN-9810327 to
BCD.
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INTRODUCTION:
Animals are composed of cells organized specifically to perform certain
functions. In order for an animal to function properly, their cells rely on constant,
carefully orchestrated communication with each other, allowing homeostasis. Cellular
regulation is accomplished through both hormonal or electrical mechanisms and direct
cell-to-cell contact. Together, these processes allow animals to balance the needs of
several body organ systems at one time.
The Pituitary
The pituitary is an endocrine gland, which secretes hormones directly into the
blood stream. Located at the base of the brain, the pituitary is fully enc losed within the
skull (Figure 1A). The pituitary rests on the sella turcica, which is a depression in the
cranial sphe noid bone, and it is divided into two lobes: the anterior pituitary and the
posterior pituitary (Netter and Hansen, 2003) (Figure 1B). The posterior pituitary serves
a neurocrine function and releases two hormones: antidiuretic hormone (ADH) and
oxytocin. ADH helps the body regulate water, while oxytocin plays a role in uterine
contraction during childbirth and allows contraction of milk glands for lactation.
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Figure 1: (A) Location of the pituitary gland: below the cerebrum and resting on
bone. (B) The division of the pituitary into the two diffe rent lobes: anterior
pituitary and posterior pituitary.

The anterior pituitary is an endocrine gland containing three different types of
cells, which are classified according to the staining characteristics of their granules:
basophils, chromophobes and acidophils (Cotran et al., 1999) (Figure 2). The basophils
take up basic stain; therefore, their granules stain blue. The basophils comprise two types
of endocrine cells: the gonadotrophs and the thyrotrophs. The gonadotrophs secrete
luteinizing hormo ne (LH) and follicle stimulating hormone (FSH), which act upon
reproductive systems in male and females. The thyrotrophs secrete thyroid stimulating
hormone (TSH), which stimulates the thyroid to produce thyroid hormone. The
chromophobes do not take up any dye and they represent one type of hormone-secreting
cells, the corticotrophs. These endocrine cells secrete adrenocorticotropic hormone
(ACTH), which stimulates the adrenal cortex to secrete cortisol, important in helping the
body respond to stress. The acidophils are the most common cell type found in the
anterior pituitary. These cells take up an acidic stain causing their granules to appear
pink. The acidophils consist of three types of hormone-producing cells: the lactrotrophs

2

somatotrophs and somatolactotrophs. The lactrotrophs produce prolactin (PRL), which
stimulates milk production in the mammary glands. The somatotrophs secrete growth
hormone (GH), which promotes growth in long bones (Cotran et al., 1999). The
somatolactotrophs can produce both GH and PRL. One characteristic of the acidophils is
that they can undergo phenotypic switching, depending on the physiological cond ition of
the animal (Kineman et al., 1992) (Figure 3).

Basophils

Chromophobes

Aci dophil s
LH/FSH

TSH
A C TH

PRL

GH

Figure 2: Three classes of anterior pituitary cells and the hormones produced
by these cells.

In mature female animals, the main stimulus to induce an increase in the
lactrotrophic acidophil population is from the hormone estrogen (Wilson, 1998; Johnson
et al., 1998). This situation applies in pregnant and post-partum females who need
prolactin to produce milk for lactation. Furthermore, the balance is shifted toward the
somatotrophs in young animals, which do not require high levels of prolactin, but must
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have growth hormone for development. Cortisol, a glucocorticoid produced by the
adrenal cortex, is known to stimulate GH secretion while decreasing PRL levels. As
these cells switch phenotypes from the lactrotrophs and somatotrophs, they undergo a
transition stage in which the cells have characteristics of both groups. These cells are
called the somatolactotrophs and the y can produce both prolactin and growth hormone.

Acidophils
Somatotr ophs

Lactotrophs
Reproductive status

PRL

Estrogen

GH
Grow th status
Glucocorticoid

Somatolactotrophs
PRL and G H
Figure 3: Phenotypoic switching of acidophil populations. Estrogen stimulates
prolactin production in mature female animals, while glucocorticoid stimulates
growth hormone in young animals.

Pituitary Regulation
A characteristic unique to the acidophils is that the lactotrophs are the only
pituitary cell type under primary inhibitory control. The lactotrophs are under tonic
dopaminergic inhibition from the hypothalamus (Johnson et al., 1998; Porter et al., 1994).
Dopamine is a catecholamine neurotransmitter found in the central nervous system.
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When it is released into the hypophysial portal blood system which connects the
hypothalamus to the pituitary gland, dopamine will inhibit prolactin secretion.
Conversely, some normal physiological conditions will stimulate prolactin secretion.
Prolactin-releasing stimuli, such as nursing, will inhibit dopamine release from the
hypothalamus, allowing pla sma levels of prolactin to rise, permitting milk production in
the mammary glands.
The adrenal glands, located at the superior pole of each kidney, also function in
the regulation of the pituitary. The adrenals produce the three classes of corticoidsteroids:
the mineralocorticoids, gonadocorticoids and glucocorticoids. Glucocorticoids are
essential for life, as they prepare an individual for stress by suppressing inflammation,
breaking down muscle to amino acids, converting amino acids and glycogen to glucose
and promoting fat metabolism. In the immune system they likewise serve as an
immunosuppressant (Cotran et al., 1999; Andreoli et al., 1997).
The most biologically active glucocorticoid is cortisol, which is a natural inhibitor
of prolactin secretion (Figure 4). Cortisol is secreted by the adrenals in response to
ACTH, which is produced by the corticotrophs. The presence of high levels of cortisol
can inhibit the corticotrophs, thus decreasing the amount of ACTH secreted through an
inhibitory feedback loop. Without the ACTH stimulation, the adrenals over time will
stop producing cortisol.
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Dopamine
from the
hypothalamus
Prolactin

Growth
Hormone

ACTH

Prolactin
and ACTH

Adrenal cortex

Cortisol
Figure 4: Normal inhibition and control of PRL and GH secretion from the anterior
pituitary.

Pituitary Adenomas
Prolactin secreting pituitary adenomas are the most common type of pituitary
tumor, which produce and secrete excess levels of prolactin (Hardman et al., 2003).
Controlling the growth of these tumors has been of clinical interest for some time due to
the mass effect of the tumor itself and the problems associated with high prolactin levels
in the bloodstream. The space inside the skull is limited and an increase in the size of the
pituitary can compress structures such as the optic nerve or cerebral blood vessels which
result in loss of vision or ischemia to parts of the brain. High prolactin levels in the

6

bloodstream can result in infertility and changes in menstruation in women and cause
impotence and gynecomastia in men.
The treatment options for prolactinomas are very limited. The primary regulation
of prolactin secretion is from dopamine secreted from the hypothalamus (Porter et al.,
1994). Therefore, the first line of treatment for pituitary tumors is through dopaminergic
drugs, such as bromocriptine, which decrease prolactin levels and lowers the growth rate
(Hardman et al., 2003). However, some pituitary tumors are not responsive to dopamine
and, therefore, more invasive procedures including radiation or surgery must be
implemented to remove the tumors. In some cases, these are still ineffective in reducing
hyperprolactinemia. Thus, finding additional means to treat dopamine resistant tumors is
of interest.
Dexamethasone
Our laboratory and others have found that the synthetic glucocorticoid analog
dexamethasone (Dex) (Figure 5) inhibits prolactin levels (Spangler and Delidow 1998;
Sakai et al., 1988). This effect is not unexpected because it is part of the normal pituitary
inhibition, where by cortisol hinders the lactotrophs from secreting PRL while
stimulating the somatotrophs to secrete GH (Figure 4). Naturally-occurring cortisone is
produced from methylation of the fourth ring on cortisol. However, the body must
convert cortisone back to active cortisol, which is used by body systems to perform
particular functions such as stimulating gluconeogenesis, or inhibiting prolactin levels
and stimulating growth hormone. Dexamethasone is a fluorinated analogue of cortisone
and in our laboratory it was used instead of cortisol because Dex has a biological half- life
of 36-54 hours, while cortisol has a half- life of 8-12 hours.
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Figure 5: Structure for cortisol the most biological active glucocorticoid.
Cortisone is formed from methylating the fourth ring and then dexamethasone is
a synthetic cortisone analogue.

235-1 Rat Pituitary Tumor Cells
The 235-1 cell line are rat pituitary acidophilic tumor cells, producing prolactin
only. These cells are a pure clone of lactotrophs and contain no somatotrophs: therefore,
these cells are unable to produce growth hormone (Delidow et al., 1992; Billis et al.,
1992). Previous work in our laboratory has shown that Dex inhibits cellular division in
the 235-1 cells by blocking late G1 stage of the cell cycle, while simultaneously
decreasing prolactin levels and decreasing cellular adhesion (Delidow et al., 2002).
Cellular Adhesion
In the 235-1 cells, prolactin levels are directly related to cellular adhesion. Cellto-cell adhesion is established by the catenin-cadherin complex, which is involved in
signaling during embryonic development and in the maintenance and function of
epithelial cell layers (Kemler, 1993; Papkoff, 1996; Hirano et al., 1992; Oyama et al.,
1994) (Figure 6).
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ß-catenin
a-catenin

Cadherin

a-catenin
ß-catenin

Figure 6: Diagram of the cadherin-catenin adhesion complex. This is a homophilic
interaction that occurs between two cells. ß-catenin provides linkage of a-catenin to
cadherin.

The cadherin-catenin adhesion complex mediates the homophilic interaction
occurring between cells at the adherens junction. Cadherin is a calcium dependent
adhesion glycoprotein, containing three domains: the extracellular cadherin repeats, a
transmembrane region, and a cytoplasmic tail. The extracellular cadherin repeats allow
communication with other cells. The cytopla smic domain interacts with linker proteins
including α-, ß- and γ-catenin (Aberle et al., 1996). The interactions between linker
proteins are necessary for establishing a connection between the adhesion complex and
the actin cytoskeleton. The linker proteins may undergo phosphorylation, which results
in the reduction or loss of cell- to-cell adhesion (Ohsugi et al., 1999). Research in our
laboratory has implicated dexamethasone (Dex) in reducing prolactin gene expression
while simultaneously altering cadherin function through the regulation of β-catenin
(Spangler and Delidow, 1998).
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Wnt Signaling
Beta-catenin is a multifunctional protein involved in both the cadherin adhesion
complex and the Wnt signaling pathway (Figure 8). ß-catenin’s structure contains three
main domains : the N-terminus, armadillo repeats, and the C-terminus (Figure 7). The Nterminus can become phosphorylated to regulate the degradation of ß-catenin, while the
C-terminus is involved in association with cadherin. There are eleven positively charged
armadillo repeats found in ß-catenin’s structure. These repeats aid in the binding of
ligands such as a-catenin and cadherin, and they are used in recognition by the tumor
suppressor protein adenomatous polyposis coli (APC) which aids in the degradation of ßcatenin.

Armadillo Repeats
N

C

Figure 7: Structure of ß-catenin showing the N and C terminus and the armadillo
repeats which are found in the center of the primary structure. The colored boxes
indicate the eleven positively charges armadillo repeat units.

In the adhesion complex, ß-catenin provides the linkage of cadherin to acatenin and the actin cytoskeleton. Cell-to-cell adhesion is dependent on the Cterminal phosphorylation state of β-catenin. In the absence of phosphorylation, the
armadillo repeats of ß-catenin can interact with its C-terminal tail or with Ecadherin. E-cadherin and the β-catenin armadillo repeats interact electrostatically,
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due to the acidic residues in cadherin and the positively charged groove in the
armadillo repeats. When β-catenin is phosphorylated at Tyr 654, the resulting steric
hindrance forces the loss of binding to E-cadherin (Piedra et al., 2001; Takeda et al.,
1995; Hoschuetzky et al., 1994) (Figure 10). In this case, ß-catenin dissociates from
the adhesion complex and can undergo either translocation to the nucleus or rapid
degradation. In the presence of Wnt signaling, secreted Wnt glycoproteins bind to
the Frizzled receptor. The signal is transduced through a cytoplasmic protein
cascade. First, the binding to the Frizzled receptor activates Dishevelled, which
inhibits glycogen synthase kinase (GSK3-ß) from phosphorylating ß-catenin (Miller
et al., 1999). Absence of this phosphorylation inhibits the formation of the

degradation complex of ß-catenin with axin, APC and GSK3-ß (Figure 8).
Ultimately activation of Wnt signaling, allows ß-catenin to be translocated to the
nucleus where it binds to T-cell factor (TCF-1), which then stimulates gene
transcription and cell proliferation (Amit, et al., 2002; Chunming, et al., 2002)
Glycogen Synthase Kinase
Glycogen Synthase Kinase (GSK3-ß) is a ubiquitously expressed
serine/threonine protein kinase. GSK3-ß participates in energy metabolism, regulating
glycogen synthesis in response to insulin (Welsh et al., 1996). GSK3-ß is involved in
neuronal cell development and plays a role in Alzheimer’s disease through the hyperphosphorylation of Tau protein, which leads to formation of amyloid plaques (Phiel et al.,
2003). Lastly, GSK3-ß is involved in the Wnt signaling pathway. In this pathway
GSK3-ß plays an important role in regulating ß-catenin. In the absence of Wnt signaling,
GSK phosphorylates ß-catenin. Once phosphorylated, ß-catenin forms a complex with
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adenomatous polyposis coli (APC) and axin, which targets the protein for proteasomal
degradation (Figure 8).

Figure 8: Diagram of Wnt signaling. The figure illustrates the pathway ß-catenin
undergoes in the presence or absence of Wnt signaling. In the presence of Wnt
signaling ß-catenin is translocated to the nucleus where it binds to TCF to initiate
gene transcription. In the absence of Wnt ß-catenin is phosphorylated by GSK3-ß
and targeted for proteasomal degradation. Illustration provided by S. Fish
Department of Anatomy, Cell and Neurobiology, Marshall University School of
Medicine.

ß-catenin Phosphorylation Sites
N-terminal phosphorylation is important for β-catenin regulation by the Wnt
signaling pathway, which takes place through the following mechanism: Casein kinase
(CK1) phosphorylates β-catenin on Ser 45, by a non-Wnt related signaling pathway, thus
priming β-catenin for further phosphorylation (Provost et al., 2003). In the absence of
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Wnt signaling, GSK3-ß targets ß-catenin for proteasomal degradation by phosphorylating
additional N-terminal (Ser 33/37 and Thr 41) sites (Figure 9). The CK1 phosphorylation
site (Ser 45) and the GSK3-ß targeted sites are conserved from Drosophila to humans.
Mutations in the N-terminal phosphorylation sites of β-catenin results in protein
stabilization, which can lead to tumorigenesis. Mutating Ser 45 results in a loss of the
priming phosphorylation on ß-catenin. This results in a reduction of the ability of GSK3β to phosphorylate ß-catenin, which then leads to a decrease in the degradation of βcatenin (Provost et al., 2003).
Ser 45
CK1

Armadillo Repeats

N
Ser 33, 37,
Thr 41
GSK3-β

C
Tyr 654

Figure 9: Diagram of phosphorylation sites on ß-catenin. C-terminal Tyr 654
phosphorylation releases ß-catenin from the adhesion complex. The N-termina l
phosphorylation sites are involved in degradation of the protein. Ser 45 is a priming
site and allows ß-catenin to be further phosphorylated on Ser 33/37/Thr41 which
targets the protein for proteasomal degradation.

Our lab has previously shown that treatment of 235-1 rat pituitary cells with
100 nM Dex causes a 50% reduction in the levels of ß-catenin by altering its half- life.
Current research has shown global reduction in nuclear, cytoplasmic and membranebound ß-catenin. There is no change in the level of total GSK3-ß, which suggests that
there is an alteration in the amount of active GSK3-ß enzyme in Dex-treated cells. In the
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current study, phosphorylation-specific antibodies were used to detect the amount of
active GSK3-β (Tyr 216) enzyme and changes in the inhibitory phosphorylation of
GSK3-ß (Ser 9). Lithium, a known inhibitor of the GSK3 family of protein kinases
(Stambolic, et al., 1996) was used to determine the effect of blocking GSK3-β enzyme
activity on ß-catenin protein levels. It is believed that glucocorticoid treated 235-1 cells
regulate ß-catenin levels by increasing the activity of GSK3-ß. Because phosphorylation
leads to the degradation of ß-catenin, phosphospecific antibodies (Ser 33/37/Thr41 and
Ser 45/Thr41) were used to examine the effects of Dex on the phosphorylation state of ßcatenin. If active GSK3-ß is increased in glucocorticoid- treated cells, it is also expected
that there will be an increase in the amount of phosphorylated forms of ß-catenin, since
these sites regulate the degradation of the protein. Additional experiments examined total
phosphorylation sites on ß-catenin in order to determine the effect of Dex on the Ser, Thr
and Tyr phosphorylation.
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Methods :

Cell Culture
The 235-1 rat pituitary cells were maintained in tissue culture flasks in DMEMhigh glucose media (Life Technologies), containing 10% iron-supplemented bovine calf
serum (Hyclone), 10 mM HEPES (pH 7.4), 100 U/mL of penicillin, 100 µg/mL of
streptomycin and 5 µg/mL of plasmocin (InvivoGen). Cells were split 1:20 once weekly
in phosphate buffered saline (PBS) containing 0.5 mM EDTA
(ethylenediaminetetraacetic acid, PBS, pH 7.4) then seeded onto 100 mm culture dishes
(Falcon). Cells were grown for a 24 hour period before the beginning of each experiment
to allow for attachment and growth.
A 1 mM stock solution of Dex (Sigma) was prepared in ethanol. A 100 µM
working solution of Dex was made by dilution in sterile PBS. Cells were treated with
100 nM Dex or vehicle (10 µL of 10% ethanol in PBS) for a period of four days. The
cells were fed and treated every two days for the duration of the experiment. In certain
experiments, duplicate cultures of control and Dex cells were treated with 20 mM LiCl
for 24 hours prior to cell collection. Cells were collected on day five by scraping;
washed once in 1 mL of PBS; then lysed and analyzed as described.

Sample Preparation
Cell pellets were lysed by sonication using the Tekmar Sonic Distruptor. Cells
were suspended in two pellet volumes (up to 180 µL) HEPES/NP-40 lysis buffer (10 mM
HEPES pH 7.5, 150 mM NaCl, 1.5 mM EDTA and 1% NP-40) containing protease
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inhibitor cocktail (Sigma: AEBSF, Aprotinin, Leupeptin, Bestatin, Pepstatin A, E-64).
The sonicator was set to an output of 45 Hz and the samples were sonicated 3X for fivesecond bursts. The phosphospecific experiments included phosphatase inhibitor cocktails
1 (Sigma: cantharidin, bromotetramisole, microcystin LR) and cocktail 2 (Sigma: sodium
orthovanadate, sodium molybdate, sodium tartrate, imidazole) in the lysis buffer. Lysates
were cleared by centrifugation. The bicinchoninic acid ( BCA) assay (Pierce) was then
employed to determine protein concentration. In this assay proteins interact with Cu2+,
forming Cu1+, and this in turn interacts with the BCA compound forming a purple color
that can be measured at an absorbance of 562 nm.

Electrophoresis and Transfer
Aliquots of 30-50 µg of protein were added to 2X SDS sample buffer (0.046%
SDS, 10% β-mercaptoethanol, 20% glycerol, 0.0125 M Tris, pH 6.8, 0.01% bromophenol
blue) and samples were separated by 10% SDS-PAGE in running buffer at 125 V for one
hour. Samples were then electroblotted onto nitrocellulose (Osmonics) in transfer buffer
at 100 V for one hour.

Western Blotting
All experiments analyzed by Western blotting were performed according to the
manufacturers’s protocols with antibodies against the protein of interest (β-catenin,
Sigma; GSK3-β, Biosource International; Phospho-GSK3-β (Ser 9), Cell Signaling;
Phospho-β-catenin (Ser 45/Thr 41) and (Ser33/35 Thr41), Cell Signaling; Phosphotyrosine (PY-20), Transduction Laboratories). The non-phosphospecific blots were
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blocked with 5% nonfat dried milk (Carnation) in TBST (10 mM Tris, pH 8.0; 150 mM
NaCl; 0.1% Tween-20) for one hour at room temperature with gentle agitation.
Phosphospecific antibodies were used at a 1:1000 dilution according to manufacturer
recommendations, in 5% Bovine Serum Albumin (BSA) in TBST at 4°C overnight.
Blots were washed three times (5 minutes each) in TBST and then incubated for an hour
at room temperature with the appropriate peroxidase- labeled secondary antibody (1:3000
in 5% milk with TBST) (Vector Labs). All additional antibodies (β-catenin and GSK3-β)
were blocked and incubated with a primary antibody dilution ranging from 1:4000 to
1:5000 in 3-5% milk in TBST; the horseradish peroxidase (HRP)-conjugated secondary
antibody was diluted 1:3000 in the same buffer. Signals were detected using enhanced
chemiluminescence (SuperSignal reagent, Pierce) and exposed on to x-ray film. Blots
were analyzed by the Personal Densitometer, using Image Quant software (Molecular
Dynamics).

Phosphatase Treatment of Cellular Extracts
Aliquots of 100 µg of protein collected from control and Dex-treated cultures
were incubated with λ phosphatase buffer (100 mM NaCl, 50 mM Tris-HCl pH 7.5, 0.1
mM MnCl2 , 0.1 mM EGTA, 2 mM dithiothreitol, 0.01 Brij 35 and 50% glycerol) and 400
U of λ phosphatase (New England Biolabs) in a reaction volume of 20 µL. The samples
were incubated at 30°C for 0-30 minutes. Samples then were mixed with an equal
volume of SDS sample buffer, denatured at 100°C and resolved on a 7.5%
polyacrylamide gel. Samples were transferred to nitrocellulose and analyzed for βcatenin by Western blotting.
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LAR Protein Tyrosine Phosphatase
Aliquots of 50 µg of protein collected from control and Dex-treated cultures were
incubated with LAR Buffer (100 mM NaCl, 50 mM Tris-HCl pH 7.0, 2 mM Na2 EDTA, 5
mM dithiothreitol, 0.01 Brij 35, 50% glycerol and purified 10 mg/ml of BSA) and 5 U of
LAR Protein Tyrosine Phosphatase (New England Biolabs) in reaction volume of 20 µL.
The samples were incubated at 30°C for 0-30 minutes. Samples then were mixed with an
equal volume of SDS sample buffer, denatured at 100°C and resolved on a 7.5%
polyacrylamide gel. Samples were transferred to nitrocellulose and analyzed for βcatenin by Western blotting.

Subcellular Fractionation
Control and Dex-treated samples were collected and washed with PBS to remove
any extra media from the cells. Five pellet volumes (up to 500 µL) of hypotonic lysis
buffer ( 20 mmol/L HEPES pH 7.5, 10 mM potassium acetate, 1.5 mM magnesium
acetate) was added to the cellular pellet. The cells were dounce homogenized (rubbed
against ground glass) for a total of 10 strokes. Samples were then subjected to low speed
centrifugation (approximately 2,000 rpms) for five minutes. After reserving the
supernatant, the pellet was resuspended in two pellet volumes (100 µL) hypotonic lysis
buffer and again subjected to low speed centrifugation two more times, with reserving the
supernatant each time. The nuclear pellet was resuspended in 1% NP-40 in PBS also
containing protease inhibitor cocktail. The pooled supernatant was centrifuged at 4 °C
for 1 hour at 13,000 rpms. The pellet containing the membrane fraction was resuspended
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in 1% NP-40 in PBS containing protease inhibitor cocktail. The supernatant represented
the cytoplasmic fraction.

Immunoprecipitation and Detection of Tyrosine Phosphorylation
Aliquots of 250 µg of protein were precleared by incubation with 0.5 µL of
normal mouse IgG (Sigma) and 20 µL protein G-agarose (Oncogene Research Products)
for 30 minutes at 30°C. The samples were subjected to centrifugation at 2,500 rpms for 5
minutes at 4°C. The supernatant was transferred to a new tube with 2 µg of β-catenin
antibody (Tranduction Laboratories) and incubated for one hour at 4°C. Protein G
agarose beads (20 µL) were added to the tubes and incubated overnight at 4°C. The
samples then were cleared by centrifugation (2,500 rpms) for five minutes at 4°C and
the pellets were washed four times with 100 µL of lysis buffer containing 100 nM
vanadate (pH 7.4). The pellet then was resuspended in 20 µL 2X SDS-PAGE sample
buffer. The samples were denatured and 10 µL of the samples were resolved on a 10%
polyacrylamide gel, transferred to nitrocellulose and analyzed for tyrosine
phosphorylation by immunoblotting.
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RESULTS:
To determine the mechanism by which glucocorticoid acts to alter the levels of ßcatenin in 235-1 cells, replicate cultures of 235-1 cells were treated with 100 nM Dex for
a period of either two or four days. Cells were collected, lysed and BCA analysis was
employed to determine protein concentration. Previous work demonstrated there is no
change in the mRNA levels of ß-catenin; therefore, we analyzed post-translational
regulation by measuring the protein level of ß-catenin by Western blotting (Fig. 10). In
this and other repeated experiments, we found that Dex causes a 50% decrease in the
expression of ß-catenin. Because previous work showed no alternation in ß-catenin
mRNA levels in Dex-treated cells, half- life studies were conducted to determine the
degradation rate of ß-catenin (Jones, R. unpublished results). Cells were treated with Dex
for two days followed by cyclohexamide (CHX) for 120 minutes. The samples were
resolved on a polyacrylamide gel, transferred to nitrocellulose and then analyzed by
Western Blotting. This revealed a decrease in the half- life of ß-catenin from twenty
minutes in control cells compared to nine minutes in Dex-treated cells.

Figure 10: Expression of ß-catenin in 235-1 cells, determined by Western blotting. Duplicate
cultures were isolated after four days from control or 100 nM Dex-treated cells. Aliquots of protein
(40 µg) were probed with antiserum against ß-catenin. A representative blot is shown. [Lanes 1 and
2 control; lanes 3 and 4 Dex]. There is a 40% decrease in ß-catenin levels in Dex-treated cells.

In glucocorticoid-treated cells, cellular morphology is altered such that the cells
appear more rounded and have shorter processes than controls (Fig. 11A). These
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alterations suggested a loss of cellular adhesion. Dex causes a decline in the growth rate
which is evident in Figure 11A, since we can see a decrease in cell numbers (Delidow et
al., 2002). Previous work in the lab also showed that treatment with Dex results in a 50%
reduction in the re-aggregation of cells (Spangler and Delidow, 1998). Phosphorylation
of Tyr 654 decreases ß-catenin binding to the cadherin-catenin adhesion complex;
therefore we examined changes in Tyr phosphorylation in both control and Dex-treated
cells. Duplicate cultures were treated for four days with Dex. Figure 11B is a
representative blot showing Tyr phosphorylated ß-catenin analyzed by
immunopreciptating ß-catenin from 250 µg of cellular protein. The blot was probed with
an anti-Tyr antibody (PY-20). This experiment revealed no changes in Tyr
phosphoryla ted ß-catenin, even though changes in cellular morphology were evident (Fig
11A). Figure 11C is a representative blot showing the removal of phosphates from
tyrosine in ß-catenin. Aliquots of protein (50 µg) were treated for 30 min with LAR
tyrosine phosphatase, which served to remove phosphates from Tyr. After gel
electrophoresis (7.5%) and transfer, the blots were probed with an antibody against ßcatenin. By running this experiment on a low percentage gel, as the phosphates are
removed there should be shifts in the protein bands due to loss of the phosphates since the
molecular weight of ß-catenin is decreasing by approximately 80 Da each time a
phosphate is removed. As shown in Figure 11C, there are no shifts in the bands due to
the loss of phosphates therefore there are no apparent alteration in Tyr phosphorylated ßcatenin. It is possible that the resolving power was not sufficient to detect the loss of
phosphates. This is because ß-catenin is not a highly Tyr phosphorylated protein. There
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are only three Tyr phosphorylated sites in the protein, therefore it may be hard to detect
the shifts in molecular weight.

A

Control

100 nM Dex

B

C

Figure 11: (A) Morphological changes induced by addition of glucocorticoid. Cells were treated
with Vehicle or Dex for four days and images were taken at 100X magnification. Dex-treated cells
are more rounded and have shorter appendages. (B) Analysis of Tyr 654 phosphorylated ß-catenin.
Aliquots of protein lysates (250 µg) were immunoprecipitated with antiserum against β-catenin.
Samples were then analyzed by Western blotting using a tyrosine specific antibody (PY-20). A
representative blot is shown. [Lanes 1, 2, 5 and 6 control; lanes 3, 4, 7 and 8 Dex]. There are no
observable changes in tyrosine phosphorylated β-catenin between the control and Dex-treated cells.
(C) Removal of phosphates from tyrosine phosphorylated ß-catenin. Duplicate cultures were
analyzed by Western blots of protein isolated from control and 100 nM Dex-treated cells. Aliquots of
protein (50 µg) were treated for 30 min with LAR Tyrosine phosphatase, which served to remove all
Tyr phosphate groups. Samples were probed with antiserum against β-catenin and a representative
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blot is shown. [Lanes 1, 2 and 3 control samples; lanes 5, 6 and 7 represent Dex-treated cells at
indicated time intervals]. There does not appear to be any difference in Tyr phosphorylated βcatenin with glucocorticoid treatment.

Beta-catenin is localized in three separate places within the cell. We attempted to
determine by subcellular fractionaltion whether glucocorticoid treatment causes any
alteratio ns in ß-catenin’s localizatio n. It is expected that Dex-treated cells will show a
decrease in cytoplasmic ß-catenin due to the increased degradation rate of the protein.
Using a cell fractionation extraction protocol, protein was isolated from the nucleus,
cytoplasm and membrane. The results in Figure 12 indicate that glucocorticoid treatment
results in a decrease in cytoplasmic, nuclear and membrane-bound ß-catenin. The
greatest percentage decrease is shown in the nucleus and membrane. The loss of any of
the linker proteins (a- or ß-catenin) from the adhesion complex results in a decrease in
cellular adhesion (Ohsugi et al., 1999). In our cell line, glucocorticoid treatment reduces
the amount of membrane bound ß-catenin. This process alone can cause a reduction in
cell-to-cell adhesion and this is evident in morphological changes that occur with
glucocorticoid treatment (Spangler and Delidow, 1998) (Figure 11A).

Figure 12: Expression of total ß-catenin localization in 235-1 cells determined by Western blots of
protein isolated from replicate cultures of control or 100 nM Dex-treated cells isolated from the
cytoplasm, nucleus and membrane. Cells were treated for two or four days and then collected.
Aliquots of protein (40 µg) were examined using a specific antibody against ß-catenin. A
representative blot is shown. ß-catenin levels were decreased in the cytoplasm, nucleus and
membrane.
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Cytoplasmic β-catenin is regulated by Wnt signaling and phosphorylation at key
N-terminal sites. To study the mechanism by which 235-1 cells regulate ß-catenin levels
we examined GSK3-ß, a kinase that phosphorylates ß-catenin, leading to proteasomal
degradation. Since ß-catenin levels are reduced by 50% when 235-1 cells are treated
with glucocorticoid, it might be expected that there is an increase in the amount of active
kinase essential to the phosphorylation of ß-catenin. We examined the levels of total
GSK3-ß in both control and Dex-treated cells. Duplicate cultures were treated with Dex
for periods of two and four days. As shown in Figure 13A, the levels of total GSK-ß
remain unchanged after four days of treatment with Dex.
In order to ascertain whether Dex treatment causes any alterations in the amount
of active GSK3-ß we examined the protein levels of Tyr 216 phosphorylated GSK3-ß.
This site is phosphorylated in active GSK3-ß (Figure 13B). After a four day treatment
with Dex, the amount of active GSK3-ß was increased two- fold. When GSK3-ß is
phosphorylated on Ser 9, the kinase activity is inhibited; therefore we wanted to note if
there is any alteration in the inhibition of GSK3-ß in the presence of Dex (Fig 13C).
When 235-1 cells are treated for a period of four days in the presence of Dex, we see a
25% decrease in the amount of the Ser 9 phosphorylated inactive GSK3-ß.

Thus,

treatment with glucocorticoid caused an increase in the amount of active Tyr 216
phosphorylated GSK3-ß, and a decrease in the amount of inhibitory Ser 9 phosphorylated
GSK3-ß. Both suggest that the 235-1 cells regulate ß-catenin levels in the presence of
Dex by increasing the activity of GSK3-ß.
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The levels of ß-catenin and GSK3-ß were then measured in the presence of LiCl,
a known inhibitor for GSK3-ß enzymes. When GSK3-ß activity is inhibited, ß-catenin
will not be targeted for proteasomal degradation. As shown in Figure 13D,
glucocorticoid treatment results in a decrease in the amount of ß-catenin with a
simultaneous increase in the amount of active GSK3-ß. However, when LiCl is added to
duplicate cultures of control and Dex-treated cells, active GSK3-ß is still present, but ßcatenin levels are restored. This suggests that while GSK3-ß can be activated in the
presence of LiCl, it is unable to phosphorylate ß-catenin.

25

A

B

C

D

26

Figure 13: (A) Expression of total GSK3 -β in 235-1 cells determined by Western blots of protein
isolated from replicate cultures of control or 100 nM Dex-treated cells. Cells were treated for two or
four days and then collected. Aliquots of protein (40 µg) were examined using a specific antibody
against GSK3 -β. A representative blot is shown. [Lanes 1, 2 and 3 control; lanes 4, 5 and 6 Dex].
The top Western blot represents a two day treatment with Dex, while the bottom Western blot
represents a four day treatment with Dex. The total level of GSK3 -β was not altered in control or
Dex-treated cells; however, β-catenin levels are reduced by 40-50% in the Dex-treated cells. (B)
Expression of active GSK3 -β (Tyr 216) in 235-1 cells. Samples were collected from duplicate cultures
of control or 100 nM Dex-treated cells. Cells were treated for four days and Western blots of protein
were probed using a phosphospecific antibody against active GSK3 -β. Aliquots of cellular protein
(40 µg) were analyzed for active enzyme. A representative blot is shown. [Lanes 1 and 2 control;
lanes 3 and 4 Dex]. The amount of active GSK3 -ß enzyme was doubled in Dex-treated cells;
simultaneously, ß-catenin expression was decreased. (C) Expression of Ser 9 phosphorylated GSK3 β. Western blots of protein (30 µg) isolated from the control or 100 nM Dex-treated cells were
probed using a phosphospecific antibody for GSK3 -β (Ser 9), which is the inhibited form. A
representative blot is shown. [Lanes 1, 2, 5 and 6 control; lanes 3, 4, 7 and 8 Dex]. Changes in
inhibitory phosphorylation between control and treated cells are visible. Dex-treated cells show a
25% decrease in inhibitory Ser 9 phosphorylation, indicative of increased GSK3 -β enzyme activity.
(D) Expression of β-catenin and active GSK3 -β. Duplicate cultures were analyzed by Western blots
of protein isolated from control, 100 nM Dex, 20 mM LiCl or LiCl and Dex-treated cells. Control and
Dex-treated cells were treated for four days and LiCl, which inhibits GSK3 -β activity, was added to
cultures one day prior to cell collection. Samples were probed using a phosphospecific antibody
against GSK3 -β phosphorylated at Tyr 216 and antiserum against β-catenin. Aliqu ots of protein (40
µg) were analyzed for β-catenin and active GSK3 -β enzyme. A representative blot is shown. [Lanes
1 and 2 control; lanes 3 and 4 Dex; lanes 5 and 6 LiCl; lanes 7 and 8 Dex and LiCl]. The top band
represents β-catenin, while the bottom band represents the active GSK3 -β enzyme. Active GSK3 -ß
enzyme was increased in Dex-treated cells; the levels of ß-catenin were decreased

Degradation of ß-catenin occurs by phosphoryla tion at key N-terminal residues,
and this phosphorylation is the key regulator of cytoplasmic ß-catenin levels (Amit et al.,
2002; Chunming et al., 2002; Provost et al., 2003). Phosphorylation of ß-catenin was
examined to determine the effects of glucocorticoid on the degradation of ß-catenin. As
shown in Figure 14A, total levels of phosphorylated ß-catenin were examined by using ?phosphatase, which removes phosphates nonspecifically from Ser, Thr and Tyr on ßcatenin over the course of 30 minutes. In both control and Dex-treated cells, phosphates
were removed in one major dephosphorylation step, evident at 0 minutes. However,
control cells needed additional time to remove further phosphates, suggesting that
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degradation of ß-catenin is occuring more rapidly in Dex-treated cells, as opposed to
control cells.
In light of these results, we examined the specific N-terminal phosphorylation
using phosphospecific antibodies. In Figure 14B, we examined Ser 45 phosphorylated ßcatenin. In this experiment cells were treated for four days in the presence of Dex and
then, on the third day, 20 mM LiCl was added to inhibit GSK3-ß activity. The results
show that glucocorticoid causes an increase in the amount of phosphorylated ß-catenin.
Treatment with LiCl induced a slight decrease in the amount of phosphorylated ß-catenin.
This is likely due to the specificity of the antibody, which recognizes a GSK3-ß targeted
site, Thr 41, as well as the non-GSK3-ß site Ser 45. We also examined the GSK3-ß
targeted sites using a phosphospecific antibody that recognizes ß-catenin only when it is
phosphorylated at Ser 33/37/Thr41 (Figure 14C). These sites become phosphorylated
only after ß-catenin is primed at Ser 45, by Casein Kinase 1. The results from this
experiment indicate that there is an increase in the amount of phosphorylated ß-catenin
when cells are treated with Dex. However, when LiCl is added to inhibit GSK3-ß
activity, there is a dramatic decrease in the amount of Ser 33/37/Thr41 phosphorylated ßcatenin. Together these data suggest that ß-catenin levels are regulated in glucocorticoidtreated cells by increasing the amount of phosphorylated ß-catenin. These results also
suggest that there are at least two different kinases that phosphorylate ß-catenin in
response to glucocorticoid leading to degradation.
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Figure 14: (A) Expression of phosphorylated ß-catenin in 235-1 rat pituitary cells. All samples were
treated for four days; protein expression from control and (100 nM) Dex was analyzed by Western
blot technique. Treatment of lysates with λ Phosphatase for 30 minutes served to remove all
phosphate groups. Samples were probed with antiserum against β-catenin. Aliquots of 100 µg of
protein were analyzed and a representative blot is shown. [Lanes 1, 2 and 3 represent control
samples at indicated time intervals. [Lanes 4, 5 and 6 represent Dex treated cells] The results show a
change in the phosphorylation states of β-catenin in both control and Dex-treated cells. λ-

29

phosphatase removed phosphates in one major step in both control and Dex-treated cells. Control
cells needed additional time to remove phosphates, as evident from the β-catenin band shifts in lanes
2 and 3. The β-catenin still present on the film indicates remaining nonphosphorylated forms.
(B) (C) Expression of phosphorylated β-catenin (Ser 45/Thr 41 and Ser33/37/Thr41). Western blots
of protein (40 µg) isolated from control, 100 nM Dex, 20 mM LiCl or Dex + LiCl-treated cells.
Control and Dex-treated cells were treated for six days and LiCl was added to cultures one day prior
to cell collection. Immunoblots were probed using a phosphospecific β-catenin antibodies, which
detects levels of β-catenin when phosphorylated at Ser 45/Thr41 or Ser 33/37/Thr41. Representative
blots are shown. [Lanes 1 and 2 control; 3 and 4 Dex; 5 and 6 LiCl; 7 and 8 Dex and LiCl]. In figure
B, there is an increase in Ser 45/Thr 41 phosphorylated β-catenin in Dex-treated cells, regardless of
the presence of LiCl. The mechanism of Ser 45 phosphorylation occurs by an alternate kinase, CK1,
which primes β-catenin for further phosphorylation by GSK3 -β. In figure C, there is an increase in
Ser 33/37/Thr 41 phosphorylated β-catenin in Dex-treated cells. In LiCl-treated cells, there is a
decrease in phosphorylated β-catenin, as lithium functions to inhibit GSK3 -β activity.

Previous work in our lab has shown that glucocorticoid treatment reduces
prolactin gene expression and causes a decrease in cellular adhesion. When 235-1 cells
are treated with glucocorticoid, we see a simultaneous decrease in prolactin and ß-catenin
levels. We wanted to determine whether there exists a common pathway relating ßcatenin and prolactin; therefore our experiments were designed to examine the effects of
LiCl on prolactin protein levels (Figure 15 A B). Cells were treated for a period of two
or four days with Dex, and 20 mM LiCl for one day. After two and four day treatment
with glucocorticoid there is a decrease in prolactin levels. Four-day control cells show an
increase in prolactin levels, possibly due to the increase in cell-to-cell adhesion. After
four days of growth the cells are confluent and they have numerous contacts with each
other. In the 235-1 cell line if the contacts between cells are increased then prolactin
levels will increase simultaneously. Treatment with LiCl slightly decreased basal
prolactin levels and did not alter the response to Dex. One possible reason for the
decrease in basal prolactin levels is because cells have been treated with Dex
simultaneously, which is known to decrease prolactin gene expression and protein levels.
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Treatment with LiCl for 24 hours may not be enough time to restore adhesion, which
would ultimately increase prolactin levels in the 235-1 cells.

A

24 kDa
2-Day

B

24 kDa
4-Day
Figure 15: Expression of prolactin in 235-1 cells. Western blots of protein (40 µg) isolated from
control, 100 nM Dex, 20 mM LiCl or Dex + LiCl-treated cells. Control and Dex-treated cells were
treated for two and four days and LiCl was added to cultures one day prior to cell collection.
Immunoblots were probed using antisera against prolactin. A representative blot is shown. [Lanes 1
and 2 control; 3 and 4 Dex; 5 and 6 LiCl; 7 and 8 Dex and LiCl]. Glucocorticoid causes a decrease in
prolactin levels. After a four day treatment with Dex, prolactin levels are practically undetectable
LiCl treatment also functioned to decrease prolactin levels slightly.
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DISCUSSION:

The data presented above support the conclusion that glucocorticoid treatment
directs numerous changes in 235-1 cells. Previous work in our lab has shown that these
changes consist of reduced prolactin gene expression, reduced prolactin protein levels,
decline in the growth rate and decreased cell- to-cell adhesion (Spangler and Delidow,
1998; Delidow et al., 2002). The change in cell- to-cell adhesion suggested that there was
a loss of the cadherin-catenin adhesion complex, although previous research was unable
to determine which cadherin was responsible in the loss of adhesion. The catenins are
partly responsible for the loss of cellular adhesion; however catenin levels are not
reduced until two days after treatment with Dex, while the loss of adhesion is evident
immediately because cells start to appear more rounded after one day treatment with Dex.
We have provided evidence that treatment with glucocorticoid decreases ß-catenin levels
by increasing at least two different kinase activities, which cause an increase in the
degradation rate of the protein.
ß-catenin is a multifunctional protein involved in the regulation of the cadherincatenin cell-to-cell adhesion complex and is an important downstream regulator of the
Wnt signaling pathway. Experimental data showed that glucocorticoid treatment causes a
50% reduction in ß-catenin protein levels (Figure 10). This reduction was due to an
alteration in the half- life of ß-catenin, without altering the mRNA levels. ß-catenin’s fate
in the cytosol is regulated by the presence of Wnt stimulation and phosphorylation.
Without Wnt signaling, ß-catenin is constantly being phosphorylation by CK1 and
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GSK3-ß, which targets the protein for degradation. ß-catenin’s half- life is twenty
minutes in the 235-1 cells before degradation; however treatment with Dex reduces ßcatenin’s half- life from twenty to nine minutes. One hypothesis is that treatment with
glucocorticoid decreases Wnt stimulation and, therefore, causes a reduction in the
cytoplasmic ß-catenin levels (Figure 12). It is also believed that similar effects are
taking place in the nucleus and membrane. Membrane-bound ß-catenin is associated in
the adhesion complex; however glucocorticoid treatment decreases cellular adhesion
while also decreasing the amount of membrane bound ß-catenin (Figure 12). This loss of
ß-catenin from the membrane may be in part responsible for the loss of cellular adhesion
and the changes in cellular morphology evident in Figure 11. In the presence of Wnt
signaling a pool of cytosolic ß-catenin is established, which then translocates ß-catenin to
the nucleus where it binds to TCF, initiating gene transcription (Provost et al., 2003;
Chunming et al., 2002). In the presence of Dex there is a decrease in the amount of
nuclear ß-catenin, due to the fact that ß-catenin’s degradation has been increased.
Likewise, there is an increase in the phosphorylated forms of ß-catenin also showing that
there is an increase in the degradation of ß-catenin (Figure 14BC).
In the absence of Wnt signaling, GSK3-ß phosphorylates ß-catenin, which then
forms a complex with the tumor suppressors Axin and adenomatous polyposis coli (APC)
leading to proteasomal degradation. Glucocorticoid treatment causes a two-fold increase
in the amount of active GSK3-ß which phosphorylates ß-catenin (Figure 13B). When
Wnt signaling is turned off GSK3-ß activity is turned on and ß-catenin’s translocation to
the nucleus is decreased. Our results show that ß-catenin levels are also regulated by the
inhibition of GSK3-ß. When GSK3-ß is phosphorylated on Ser 9, the kinase is inactive
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and will not phosphorylate ß-catenin. Treatment with glucocorticoid decreased the
amount of inhibited GSK3-ß by 25% (Figure 13C). It is believed that both the decrease
in inhibitory Ser 9 phosphoryla tion and increase in active Tyr 216 phosphorylation of
GSK3-ß both control the regulation of ß-catenin in the 235-1 cells.
Abnormalities in Wnt signaling or mutations in the N-terminal phosphorylation
sites (exon 3) cause an accumulation of cytosolic ß-catenin whic h initiates gene
transcription and can ultimately lead to tumorigensis since the whole signaling process is
up regulated. The four serine/threonine residues (Ser 33/37/45 and Thr 41) are conserved
from Drosophilia to human and mutations in these N-terminal phosphorylation sites are
observed in many types of human tumors (Chunming et al., 2002). Research has found
that all such mutations are associated with malignant types of tumors, but there are two
different mechanisms by which ß-catenin is involved in precipitating colon cancer. Some
colon cancer research has found that there is a mutation in the APC complex, while
others has found mutations in the specific N-terminal phosphorylation sites. When ßcatenin is mutated in exon three, it is unable to bind to the F box protein ß-Trcp, which is
the ubiquitination apparatus (Liu, 2002). Therefore, ß-catenin accumulates in the cytosol
eventually turning on gene transcription.
This work has provided further evidence that there are at least two different
kinases involved in the phosphorylation of ß-catenin leading to degradation. When cells
are treated for a period of four days with Dex and one day with LiCl, there is an increase
in the amount of phosphorylated ß-catenin. However, when duplicate cultures are treated
with Dex and LiC l, our results indicate that Ser 45 phosphorylation is still detectable
(Figure 14B). This suggests that Ser 45 is phosphorylated by a kinase other than GSK3-
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ß, since it is not inhibited by LiCl. Research has shown that in vivo Ser 45 is
phosphorylated by CK1 and it functions as a priming site on ß-catenin. When CK1 is
deleted, ß-catenin is unable to become phosphorylated and ultimately degraded
(Chunming et al., 2002; Amite et al., 2002). It has also been found that without CK1
phosphorylation the GSK3-ß targeted sites are unable to become phosphorylated, which
can also lead to stabilization of ß-catenin. This demonstrates the important role of at least
two different kinases, but also stresses the importance of individual residues in ß-catenin.
Furthermore, when cells are treated with Dex, there is an increase in Ser 33/37/Thr 41
phosphorylation. However, when cells are treated with Dex and LiCl few forms of Ser
33/37/Thr41 phosphorylated ß-catenin remain (Figure 14C). These sites are GSK3-ß
targeted sites and are inhibit ed by LiCl. These results provide more evidence to support
the conclusion that two kinases regulate ß-catenin activity.
A question stemming from this research is how a corticosteroid can activate a
kinase? One potential mechanism could be through Akt signaling, which regulates cell
fate between survival and apoptosis and is also involved in glycogen synthesis.
Corticosteroids, insulin, and other growth factors have been shown to activate the Akt
signaling through tyrosine kinases or G-protein coupled receptors ( Langdown, 2001;
Burgering and Coffer,1995; Franke et al., 1995) Once Akt is activated it can
phosphorylate a number of substrates involved in inhibiting apoptosis. One such substrate
phosphorylated by Akt is GSK3-ß (Hajduch et al., 2000; Cross et al., 1995). GSK3-ß
regulates ß-catenin’s cellular fate, is involved in regulating glycogen synthesis in
response to insulin (Welsh et al., 1996), and is involved in cell cycle regulation by
preventing phosphorylating of cyclin D1 (Diehl et al., 1998). If GSK3-ß is
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phosphorylated by Akt, it demonstrates that cross talk between Wnt signaling and Akt
signaling exists. A potential technique to look at the interactions of the two pathways
would be to block Akt activity to see what alterations occur with GSK3-ß.
Another area of interest from this research is how CK1 is activated by a
glucocorticoid? Our research and others have shown that in order to regulate ß-catenin
levels, CK1 must be first activated before GSK3-ß can phosphorylate ß-catenin (Amit et
al., 2002; Chunming et al., 2002). Additional studies have shown that CK1 appears to
play a role in glycogen me tabolism in response to insulin (Bacskai et al., 1993; Tuazon,
and Traugh 1991; Osterrieder et al., 1982) and the δ isoform of CK1 has been shown in
vitro to play a role in the hyperphosphorylation of Tau therefore playing a role in
Alzheimer’s disease (Schwab et al., 2000; Ghoshal et al., 1999). The possible connection
is that since GSK3-ß is also involved in these processes then there must be an interaction
between these two kinases. However the direct mechanism is unknown. One reason why
it is difficult to find out how CK1 and GSK3-ß are related is due to the fact that CK1
undergoes autoregulation. This autophosphorylation is main type of regulation for this
kinase and therefore it is difficult to determine what affects this autophosphorylation or
what signal activates or inactivates this kinase.
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CONCLUSIONS:
In conclus ion, these data suggest that glucocorticoid acts post-translationally to
alter the level of β-catenin in 235-1 cells by increasing at least two kinase activities. βcatenin phosphorylation takes place in two steps: first, it must be primed at Ser 45 by
CK1; next, β-catenin is phosphorylated by GSK3-β at Ser 33, 37 and Thr 41, which
targets the protein for degradation. Our data show that Dex increases the level of active
GSK3-β and decreases the amount of inhibitory GSK3-ß. The mechanism of increased
Ser 45 phosphorylation will be the focus of further study to ascertain whether there is an
alteration in expression or activation of CK1, the putative kinase for this site. It is
important to determine the mechanism by which CK1 regulates GSK3-ß activity, since
Ser 45 must be primed first before GSK3-ß can phosphorylate its targeted sites. Future
studies also include looking at the gene targets of ß-catenin to determine whether
prolactin is one of the targets of expression.
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